



Haus der Wirtschaft, conference venue

EUROPEAN  
SCIENCE  
FOUNDATION

ECT  
A EUROCORES PROGRAMME  
EUROPEAN SCIENCE FOUNDATION COLLABORATIVE RESEARCH

This conference, as part of the European Science Foundation EUROCORES Programme ECT, is supported by funds from the EC Sixth Framework Programme, under Contract no. ERAS-CT-2003-980409

## **Pan European Sarcoma Trials: Moving forward in a climate of increasing economic and regulatory pressure**

### **Preliminary programme and registration form**

**Haus der Wirtschaft, Stuttgart  
30 November – 2 December 2006**



Klinikum Stuttgart

**Stefan Bielack**  
ECT-Project Leader, Euro-  
pean and American Osteo-  
sarcoma Study (EURAMOS)



## About this conference

The interdisciplinary treatment of osteo-, Ewing's, and paediatric soft tissue sarcoma in Europe and North America is routinely administered within the framework of prospective multicentre trials. These trials, which are increasingly multinational, are of pivotal importance for the advancement of knowledge and also function as essential quality assurance instruments.

Since EU member states are now obliged to have laws and administrative procedures in place to comply with GCP under EU Directive 2001/20/EC, the challenge to make advances has become greater than ever. Institutions conducting non-commercial clinical trials are struggling to cope with logarithmic increases of administrative and financial burdens. Add to this the reality that implementations of the Directive at the national level were very heterogeneous, concerns about the problematic issues of sponsorship, high costs for proband insurance, fees for ethics committees and competent authorities, sometimes prohibitive bureaucratic workloads associated with pharmacovigilance and source data verification, as well as the lack of paediatric licensing for many marketed drugs, the progress of existing trials is jeopardised and the initiation of new European studies has all but come to a standstill.

High quality clinical research requires the involvement not only of motivated and skilled clinicians, but also numerous partners, including academic networks, national regulatory authorities, ethics committees, national and international funding organisations, pharmaceutical companies, The European Commission and charities. It is essential that all parties involved in clinical trials collaborate on an international scale and it is for this reason that we have incorporated an "economic and regulatory" session into the programme which culminates in a roundtable discussion involving representatives from each of these groups.

In this conference we provide an overview of currently active and planned multinational sarcoma studies in Europe as well as explore and seek solutions for the challenges resulting from the current economic and regulatory environment.

In summary, this conference aims not only to present the most up to date scientific results but also to provide a forum to examine the challenges and opportunities facing existing pan-European sarcoma trials, to compare and benchmark practice and results and to advance non-commercial clinical trials within the international sarcoma community.

On behalf of the Organising Committee, I extend to you a very warm welcome to Stuttgart!

Stefan Bielack



## Programme at a glance

### Organising committee

- S. Bielack, Stuttgart, Germany
- G. Calaminus, Düsseldorf, Germany
- H. Jürgens, Münster, Germany
- T. Klingebiel, Frankfurt Germany
- E. Koscielnaik, Stuttgart, Germany
- M. Resnicoff, European Collaborative Research Programme in Medical Sciences, European Science Foundation
- S. Smeland, Oslo, Norway
- J. Whelan, London, UK

### Local organisation and further information

Lynn Hazlewood  
 Secreteriat Prof. Bielack  
 Dept. of Oncology, Haematology, Immunology  
 Olgahospital, Centre for Paediatric Medicine  
 Bismarckstr. 8  
 70176 Stuttgart

Tel. + 49 711 992 2466  
 Fax. +49 711 992 2462  
 Email. l.hazlewood@olgahospital.de

### Thursday, 30 November 2006

13:00 - 18:15	Registration
13:00 - 14:00	Light buffet lunch
13:30 - 18:15	Quality of life – concluding in a viewing of artwork from the project "Bringing Medicine to Life"
15:30 - 16:00	Coffee break
19:00 - 20:30	Reception hosted by K.-P. Murawski, the Deputy Mayor for Administrative Services and Municipal Hospitals
20:30	Speakers' dinner

### Friday, 1 December 2006

07:30 - 08:30	Registration
08:30 - 09:00	Welcome ceremony
09:00 - 12:30	The regulatory and economic environment for clinical trials in Europe
10:25 - 10:55	Coffee break
12:30 - 13:30	Lunch/press conference
13:30 - 16:00	Osteosarcoma
16:00 - 16:30	Coffee break
16:30 - 18:30	Intergroup projects and strategies
20:00	Networking dinner

### Saturday, 2 December 2006

08:00 - 09:00	Registration
09:00 - 11:30	Soft Tissue Sarcoma
11:30 - 12:30	Brunch
12:30 - 15:00	Ewing's sarcoma
15:00 - 16:00	Roundtable discussion

Registration deadline:  
 15 November 2006



**Klaus-Peter Murawski**  
Deputy Mayor for Administrative  
Services and Municipal Hospitals, Stuttgart

**Heribert Jürgens**  
President, German Society of  
Paediatric Oncology and  
Haematology, Intergroup Chairman,  
EURO-E.W.I.N.G. 99



## Welcome

With its in-patient capacity of some 5,500 beds spread over 19 clinics, as well as numerous private companies and vocational training facilities in the health sector, the City of Stuttgart, capital of the state of Baden-Wuerttemberg is an important centre for health care. The City of Stuttgart is the body responsible for almost 50 per cent of in-patient facilities in Stuttgart, provided by Klinikum Stuttgart, a clinical centre comprising four hospitals. This clinical centre offers a full range of clinical departments and services and is associated with the highest quality standards in health care including state-of-the-art medical technology.

The treatment of children suffering from cancer at the Olgahospital, Stuttgart's paediatric centre, enjoys an outstanding reputation way beyond the confines of our city. This is not only due to the excellent therapy and care offered there; scientific research activities are firmly anchored in the Olgahospital's tradition and have contributed to the centre's overall success. I am therefore delighted that the City of Stuttgart, home of the COSS and CWS study centres, serves as the venue for the congress "Pan European Sarcoma Trials" and I want to extend a warm welcome to all of you.

The comprehensive and diverse congress programme covers the entire range of issues related to sarcoma research and a special focus will be given to the presentation of international study results. Another issue to be explored is that of funding, and, something which I personally consider to be of utmost importance, the quality of life of our young patients.

I want to take this opportunity to thank the congress organisers, especially the European Science Foundation, which has provided the funds for this congress through the ECT EUROCORES Programme and Prof. Dr. Bielack and his staff for taking care of the practical arrangements to make this congress possible.

During the FIFA World Cup 2006, Stuttgart served as a cosmopolitan host city for guests from around the world. I hope that your stay in Stuttgart will be just as enjoyable. On 30. November 2006, following the first day of the scientific programme, it gives me great pleasure to invite you to a civic reception which I will be hosting at Stuttgart's City Hall. I look forward to having the opportunity to welcome you, as medical professionals and researchers on that evening.

Klaus-Peter Murawski

## Worldwide, treatment within large-scale clinical trials has become standard in Paediatric Oncology.

This was the basis for the breakthrough and impressive improvements in disease-free survival for many paediatric cancers including sarcomas. Within such trials risk strata have been identified necessitating different treatment strategies. In rare diseases and, even more so, in subgroups of such diseases international co-operation is essential to generate evidence for the efficacy of treatments given. Across Europe, the national groups working on sarcoma research have joined in developing clinical trials in a well-orchestrated effort. We are now faced with new, challenging European and national legislation governing these clinical trials and with a host of bureaucratic demands on the co-ordinators and managing staff as well as clinical investigators in the treatment centres. At this Stuttgart meeting let us explore grounds for hope that we may go on to realise the guidelines of Good Clinical Practice while continuing to develop sophisticated therapy for the benefit of our patients.

Heribert Jürgens



**Klaus-Peter Baatz**  
Chairman, Förderkreis Krebskranke  
Kinder e.V., Stuttgart



**Claude Krier**  
Medical Director,  
Klinikum Stuttgart

## Welcome to Stuttgart – the home of Baden Württemberg’s much cherished paediatric children’s hospital, the Olgahospital.

My compliments to the organisers of this meeting, particularly Professor Bielack, Professor Koscielniak, Professor Klingebiel and Professor Jürgens, for compiling a formidable programme of lectures and discussion in which we can hear the latest news from the most important three international paediatric sarcoma trials taking place in Europe today. As chairman of a charity I am particularly looking forward to the session and round-table discussion on the topic of the regulatory and economic environment for clinical trials in Europe. While there is a tremendous amount of goodwill in the public domain and indeed, the population of Stuttgart is one of the most generous donating publics in Germany, there is no doubt that the economic environment is becoming increasingly hard and that the long-term survival of clinical trials such as those we will hear about during this meeting is under threat.

On behalf of the Förderkreis für Krebskranke Kinder I extend my thanks to the organisers of this important meeting and a very warm welcome to all participants from near and far.

Klaus-Peter Baatz

## On behalf of the Managing Directorate and the Medical Board of Klinikum Stuttgart, it is a great pleasure to welcome participants of the meeting “Pan European Sarcoma Trials” to Stuttgart.

In this meeting clinical researchers, data managers and specialists from different fields will learn from each other and thus improve the quality of diagnosis and therapy in paediatric sarcoma patients. It is a great honour for the city of Stuttgart and Klinikum Stuttgart to play host to clinicians and scientists involved in the interdisciplinary and multinational treatment of bone and soft tissue sarcoma, especially in children, from all over Europe and beyond.

In the last years we have seen increasing cost pressure on health care delivery systems all over Europe. On one hand this is due to demographic changes, and on the other hand to advances in medical technology. In the field of oncology especially, financial and ethical issues are becoming very important in clinical decisions. There is an increasing need for effective use of resources and accordingly for evidence-based principles in medicine. Multinational trials help us address the need to monitor effectiveness, to carry out benchmarking and to establish best practice, thus giving the best possible benefit to patients with tumour disease.

All over Europe health care systems are in transition and there is increasing pressure for the scientific community to set priorities, reevaluate diagnostic and therapeutic programmes in the light of evidence-based principles and to learn from interdisciplinary and multinational networks. In this sense I wish your meeting every success in contributing towards overcoming these challenging goals.

Last but not least I want to address my thanks to Prof. Bielack and the organising committee for having chosen Stuttgart as the meeting location. I wish all participants a very pleasant and productive stay in our beautiful city. Enjoy not only the interchange of new scientific ideas, but also the opportunity to meet old friends and make new ones and to discover the charming sites and the culture of Stuttgart and our region.

Claude Krier



**Mariana Resnicoff**  
Coordinator, European Collaborative  
Research (EUROCORES) Programme  
in Medical Sciences,  
European Science Foundation

It is my pleasure to welcome you to the conference **Pan-European Sarcoma Trials: Moving forward in a climate of increasing economic and regulatory pressure.**

We are gathered in Stuttgart to discuss quality of life and state-of-the-art in the treatment of sarcoma patients as well as the challenges for pan-European academic trials under the current regulations.

We are all aware that academic clinical trials play a pivotal role in the development of new therapeutic modalities. Cancer is a good example where academic trials are not only one of the major frameworks for diagnostics and therapeutics, but also for patient care. Clinical trials in Europe are mainly funded on a national basis; however, a number of those trials would be much more valuable if performed at a larger scale across Europe, drawing on funding from several countries. This is particularly relevant for clinical trials on rare diseases that require multi-centre collaborations to increase patient recruitment and the size of the trial. The implementation of the European Directive 2001/20/EC has increased the administrative and financial burden, delaying the onset of pan-European academic trials, further aggravated by the heterogeneity of national legislation across European countries.

By bringing together clinical researchers, statisticians, data managers, paediatric and adult oncologists, pathologists, radiologists and surgeons involved in three multi-national sarcoma trials with representatives from European and national regulatory agencies, funding organisations, charities and professional associations, we intend to create a platform for pan-European sarcoma trials. This is a unique opportunity to learn from each other's experience, to compare results and benchmark best practice, to establish a forum for constructive discussions and work together to circumvent the current difficulties. The outcome and impact of this meeting rely on your contribution, so I encourage you to make the most of these two days.

Mariana Resnicoff



## Programme

### Thursday, 30 November

Studio A, 3 Floor

**13:00 - 18:15**

**Registration**

**13:00 - 14:00**

**Lunch**

**13:30 - 18:15**

**Bringing quality into life: Views and perspectives in sarcoma patients**

Chairpersons:

- G. Calaminus, Düsseldorf, Germany
- W. Furlong, Hamilton, Canada

**13:30 - 14:00**

**Quality of life in children and adolescents**

U. Ravens-Sieberer, Berlin, Germany

**14:00 - 14:30**

**Quality of life in adolescents and young adults with cancer: needs and perspectives**

C. Eiser, Sheffield, UK

**14:30 - 15:00**

**Quality of life in adolescents and young adults with cancer: the socio-economic approach**

W. Furlong, Hamilton, Canada

**15:00 - 15:30**

**Quality of life in patients with soft-tissue sarcoma**

M. Jenney, Cardiff, UK

**15:30 - 16:00**

**Coffee break**

**16:00 - 16:30**

**Quality of life in patients after treatment for osteosarcoma**

R. Nagarajan, Cincinnati, USA

**16:30 - 17:00**

**Structural approach of quality of life estimation within multinational trials: The EURAMOS Experience**

G. Calaminus, Düsseldorf, Germany

**17:00 - 17:30**

**Discussion: Quality of life research: An integral component of paediatric sarcoma trials**

Unless otherwise specified, all working sessions will take place in the König-Karl-Halle

**17:30 - 17:50**

**Clinical trials in osteosarcoma treatment:  
Patients' perspectives through art**

L. Burns, London, UK

M. Perisoglou, London, UK

**17:50 - 18:15**

**Viewing of artwork from the project  
"Bringing Medicine to Life"**

**19:00 - 20:30**

**Reception hosted by Klaus-Peter Murawski, the  
Deputy Mayor for Administrative Services and  
Municipal Hospitals, in Stuttgart's City Hall**

**20:30**

**Speakers' dinner in the wine cellar of Stuttgart's City  
Hall**

## Friday, 1 December

**07:30 - 08:30**

**Registration**

**08:30 - 09:00**

**Welcome ceremony**

Moderation: S. Bielack, ECT-Project Leader, European and American Osteosarcoma Study (EURAMOS)

- K.-P. Murawski, Deputy Mayor for Administrative Services and Municipal Hospitals, Stuttgart
- H. Jürgens, President, German Society of Paediatric Oncology and Haematology
- K.-P. Baatz, Chairman, Förderkreis Krebskranke Kinder e.V.
- C. Krier, Medical Director, Klinikum Stuttgart
- M. Resnicoff, Coordinator, European Collaborative Research Programme in Medical Sciences, European Science Foundation

**09:00 - 12:30**

**The regulatory and economic environment for  
clinical trials in Europe**

Chairperson:

H. Jürgens, President of the German Society for Paediatric Oncology and Haematology

**09:00 - 09:10**

**Introduction**

S. Bielack, ECT-Project Leader, European and American Osteosarcoma Study (EURAMOS)

**09:10 - 09:25**

**Challenges presented by applying current regulations to  
the day to day running of trials**

K. Pritchard-Jones, Chairperson, SIOP Europe Clinical Trials Committee, London, UK

**09:25 - 09:40**

**Interpretation and implementation of EU legislation at  
the national level – the regulatory view**

C. Steffen, Head, Clinical Trials and GCP Inspections Unit, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany

**09:40 - 09:55**

**Interpretation and implementation of EU legislation at  
the national level – the paediatric clinician's perspective**

H. Jürgens, President of the German Society for Paediatric Oncology and Haematology, Münster, Germany

**09:55 - 10:10**

**Licensing and availability of standard drugs in paediatric  
oncology – the regulatory perspective**

**10:10 - 10:25**

**Coordination of funding at the pan-European level –  
the EUROCORES ECT Programme**

M. Resnicoff, European Collaborative Research Programme in Medical Sciences, European Science Foundation

**10:25 - 10:55**

**Coffee break, König-Karl-Halle Foyer**

**10:55 - 11:10**

**National funding agencies: Funding of clinical trials by  
the German Research Foundation (DFG)**

A. Schmidtman, Life Sciences Group, Deutsche Forschungsgemeinschaft, Bonn, Germany

**11:10 - 11:25**

**Public funding of clinical trials: Overcoming hurdles to  
create strong collaborative networks**

R. Sullivan, Clinical & Translational Research Directorate, Cancer Research, UK

**11:25 - 11:40**

**Support from charitable organisations in Germany**

G. Nettekoven, Project Aid Directorate, Deutsche Krebshilfe, Bonn, Germany

# Programme

## Friday, 1 December

**11:40 - 12:30**

**Roundtable discussion: Balancing the needs of patient oriented clinical research with the demands of the regulatory environment**

**12:30 - 13:30**

**Press Conference, Raum Ulm, 2 Floor**

**12:30 - 13:30**

**Lunch, König-Karl-Halle Foyer**

**13:30 - 16:00**

### **Osteosarcoma**

Organised by the Cooperative Osteosarcoma Study Group (COSS)

Chairpersons:

- S. Bielack, Stuttgart, Germany
- S. Smeland, Oslo, Norway

### **Results from multinational osteosarcoma trials**

**13:30 - 13:40**

**Skip metastases are not associated with a dismal prognosis**

L. Kager, Vienna, Austria

**13:40 - 14:00**

**Dose intensity in osteosarcoma therapy: does it matter?**

- COSS: Results from a retrospective analysis of 917 patients  
S. Bielack, Stuttgart, Germany
- EOI: Results from a prospective trial of doxorubicin /cisplatin +/- G-CSF  
I. Lewis, Leeds, UK

**14:00 - 14:10**

**Updated results of the prospective multicentre trial COSS-96**

S. Bielack, Stuttgart, Germany

**14:10 - 14:20**

**Questions to the speakers**

### **The European and American Osteosarcoma Study EURAMOS1**

**14:20 - 15:20**

- Introduction: S. Bielack, Stuttgart, Germany
- Recruitment update from the coordinating data centre: M. Sydes, London, UK
- Report from the Cooperative Osteosarcoma Study Group (COSS), D. Carrle, Stuttgart, Germany

- Report from the European Osteosarcoma Intergroup (EOI), J. Whelan, London, UK
- Report from the Scandinavian Sarcoma Group (SSG), S. Smeland, Oslo, Norway
- Report from the Children's Oncology Group (COG), N. Marina, Stanford, USA
- Update on Germany: S. Bielack, Stuttgart, Germany
- Update on Austria: A. Zoubek, Vienna, Austria
- Update on Switzerland: T. Kühne, Basel, Switzerland
- Update on Hungary: S. Pápai, Budapest, Hungary
- Update on applicant countries: A. Holliday, London, UK
- Joining EURAMOS-1 – from the perspective of applicant countries: J. Stary, Prague, Czech Republic, W. Wozniak, Warsaw, Poland

**15:20 - 15:30**

**Discussion: Challenges and opportunities of international collaboration**

### **EURAMOS networking amongst osteosarcoma groups**

**15:30 - 15:40**

**EUROBOSS: Standardised treatment for older patients with osteosarcoma**

S. Ferrari, Bologna, Italy

**15:40 - 15:50**

**The European Relapsed Osteosarcoma Registry (EURELOS)**

C. Int-Veen, Stuttgart, Germany

**15:50 - 16:00**

**Networking clinical osteosarcoma trials with basic research in the EUROBONET work package**

H. Bürger, Münster, Germany

**16:00 - 16:15**

**Discussion: EURAMOS as a platform for integrative osteosarcoma research**

**16:15 - 16:45**

**Coffee break**

**16:45 - 18:30**

### **Intergroup projects and strategies**

Chairpersons:


- M. Bernstein, Montreal, Canada
- M. Paulussen, Basel, Switzerland

**16:45 - 17:00**

**Pharmacovigilance in sarcoma trials**

T. Butterfaß-Bahloul, Münster, Germany





## Programme

**17:00 - 17:15**

**Assessing quality of life in sarcoma trials**

G. Calaminus, Düsseldorf, Germany

**17:15 - 17:30**

**Functional impact of surgery on sarcoma patients**

C. Gebert, Münster, Germany

**17:30 - 17:45**

**State of the art in the surgical therapy of lung metastases**

K. Diemel, Grosshansdorf, Germany

**17:45 - 18:00**

**Comparison of treatment concepts for extrasosseous Ewing's sarcoma between soft-tissue and bone sarcoma trials**

R. Ladenstein, Vienna, Austria

**18:00 - 18:15**

**Late effects surveillance system (LESS)**

T. Langer, Erlangen, Germany

**18:15 - 18:30**

**Questions to the speakers**

**20:00**

***Dinner at the Plenum (Landtag) Stuttgart with an address from M. Caspers-Merk, Parliamentary Minister of State, German Department of Health***

## Saturday, 2 December

**09:00 - 11:30**

**Soft Tissue Sarcoma**

Organised by the Cooperative Soft Tissue Sarcoma Study Group (CWS)

Chairpersons:

- E. Koscielniak, Stuttgart, Germany,
- T. Klingebiel, Frankfurt, Germany

**09:00 - 09:15**

**European challenges in establishing a pan European protocol for localised rhabdomyosarcoma**

M. Stevens, Bristol, UK

**09:15 - 09:30**

**Implementation of European regulations at a national level: barriers to establishing a pan European protocol for localised rhabdomyosarcoma**

E. Koscielniak, Stuttgart, Germany

**09:30 - 09:45**

**Adjuvant chemotherapy in synovial sarcoma and other non-RMS soft tissue sarcoma: a yet to be resolved controversial issue**

I. Brecht, Stuttgart, Germany

**09:45 - 10:00**

**Treatment of metastatic soft tissue sarcoma within the CWS group. Results of the CWS-96 IV Study**

T. Klingebiel, Frankfurt/Main, Germany

**10:00 - 10:15**

**Results of the randomised study for localised "high risk" rhabdomyosarcoma. Report of the CWS-96 and ICG-96 Studies**

T. Dantonello, Stuttgart, Germany

**10:15 - 10:30**

**Innovative irradiation methods and their role in the treatment of children with soft tissue sarcoma**

A. Schuck, Münster, Germany

**10:30 - 10:45**

**How to realise common European biological research projects for soft tissue sarcoma within the European Soft Tissue Sarcoma Study Group**

A. Rosolen, Padua, Italy

**10:45 - 11:00**

**Clinical relevance of molecular diagnosis in rhabdomyosarcoma. Retrospective analysis of the CWS-Studies**

S. Stegmaier, Stuttgart, Germany

**11:00 - 11:30**

***Discussion: Achieving progress in soft tissue sarcoma through European cooperation***

**11:30 - 12:30**

***Brunch***

**12:30 - 15:00**

**Ewing's Sarcoma**

Organised by the EURO-E.W.I.N.G. 99 Study Group

Chairman:

H. Jürgens, Münster, Germany

## Programme

### Saturday, 2 December

12:30 - 12:45

**Basic requirements in the conventional pathological workup of Ewing tumours, response evaluation**  
G. Köhler, Münster, Germany; P. Hogendoorn, Leiden, The Netherlands

12:45- 13:00

**Current initiatives, targets and markers in Ewing's sarcoma biology**  
H. Kovar, Vienna, Austria

13:00 - 13:15

**EICESS 92 – Global results and results according to local therapy**  
J. Whelan, London, UK

13:15 - 13:30

**EICESS 92 – Results according to age and institution**  
M. Paulussen, Basel, Switzerland

13:30 - 13:45

**Interim report on EURO-E.W.I.N.G. 99**  
H. Jürgens, Münster, Germany

13:45 - 14:15

**EURO-E.W.I.N.G. 99 - R3 results**  
R. Ladenstein, Vienna, Austria

14:15 - 14:30

**Ewing tumours in infants**  
H. van den Berg, Amsterdam, The Netherlands

14:30 - 14:45

**The value of FDG-PET in staging and response evaluation**  
C. Franzius, Münster, Germany

14:45 - 15:00

**The value of treosulfan in the treatment of high-risk Ewing tumours**  
U. Dirksen, Münster, Germany

15:00 - 16:00

**Roundtable discussion:**

**Distinct diseases, common challenges: Synergy between bone and soft tissue sarcoma groups**

Moderator: M. Paulussen, Basel, Switzerland

Speakers include: M. Bernstein, S. Bielack, H. Jürgens, T. Klingebiel, E. Koscielniak, N. Marina, S. Smeland, J. Whelan

## General Information

### Registration

Places are limited and will be allocated on a first come, first served basis. There is no registration fee. The registration deadline is **15. November 2006**.

### Venue

The conference venue is the city centre, within a short walk of Stuttgart's main railway station.

### Address

Haus der Wirtschaft  
Willi-Bleicher-Straße 19  
D-70174 Stuttgart  
www.hausderwirtschaft.de

### Financial support for participants

Participants caring for patients registered in the EURAMOS and PROFIDYS trials may apply for accommodation and travel expenses to be funded by the Eurocores ECT programme. If you are eligible for this offer please complete the appropriate sections on the registration form.

### Hotel accommodation

Delegates not applying for ESF funding are advised to arrange their hotel accommodation through [www.stuttgart-marketing.de](http://www.stuttgart-marketing.de)

### Language

The conference language is English. There is no simultaneous translation.

### Continuing Medical Education (CME) points and certificate of attendance

The Landesärztekammer (Medical Council) Baden Württemberg has awarded this conference 23 CME points. A certificate of attendance will be issued at the conference.



### Climate

As Stuttgart can be very cold in December warm clothing is recommended.

### Insurance / disclaimer

The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements with regards to insurance. The organisers reserve the right to alter or cancel, without prior notice, the congress or any arrangements relating directly or indirectly to it. The organisers shall not be liable for any loss, damage, expenditure or inconvenience caused as a result of such alterations or cancellation. The programme is correct at the time of printing. However, the organisers reserve the right to alter the programme if necessary.

# Registration form

## Pan European Sarcoma Trials: Moving forward in a climate of increasing economic and regulatory pressure

Registration deadline: **15 November 2006**

Title / name

---

Position

---

Accompanying person  
(social events only)

---

Institution

---

Postal address

---

Telephone

---

Fax

---

Email

---

Please indicate the trials in which your Institution has patients registered

EURAMOS                       PROFIDYS                       CWS                       EURO-E.W.I.N.G.

---

Do you wish to apply for your accommodation and travel expenses to be funded by the Eurocores ECT programme?\*

yes                       no

If yes, please provide an estimate of your travel expenses (without hotel, this will be arranged by the organisers)

---

Anticipated arrival date

29 November 2006                       30 November 2006                       1 December 2006

---

Anticipated departure date (close of meeting approx. 16:00)

2 December 2006                       other \_\_\_\_\_ (please specify)

---

I will attend the Reception at the City Hall on 30 11.06

yes                       no

---

I will attend the networking dinner on 01 12.06

yes                       no

---

Special dietary requirements/special hotel requests

---

Comments

---

\*applicable to participants with patients registered in the EURAMOS and PROFIDYS trials

> **Please return this form by 15 November 2006 (see overleaf)**

Please return your registration by fax to  
+49 (0)711 992 2462 or by post:

### Olgahospital

Centre for Paediatric Medicine  
Lynn Hazlewood  
Secretariat Prof. Bielack  
Dept. of Oncology, Haematology, Immunology  
Bismarckstr. 8

D-70176 Stuttgart



Stuttgart's City Hall - venue of the reception and speakers' dinner on 30.11.2006



## Pan European Sarcoma Trials: Moving forward in a climate of increasing economic and regulatory pressure

A forum to examine the challenges and opportunities facing existing European sarcoma trials, to compare and benchmark best practice and to advance cooperation within the European sarcoma community

### Who should attend:

- Clinical researchers from European institutions which treat sarcoma patients and register these into clinical trials. This programme is aimed not only at senior clinicians, but also at more junior doctors who are dealing with the issues on a local, institutional level. Your participation in the conference will raise the overall level of expertise and increase your awareness of ongoing efforts to run or to initiate multinational sarcoma trials.
- Clinical researchers, statisticians and data managers from the study centers of European trial groups which are actively conducting multi-center, international and inter-group trials. Your attendance will strengthen existing networks and assist in the foundation of new collaborations. It will also teach you about strategies for enabling the progress of trials in the current economic and regulatory environment.
- Specialists from a variety of fields involved in the interdisciplinary treatment of bone and soft tissue sarcoma. Your attendance will enable you to learn about the latest results and developments of state of the art sarcoma therapies. It will also provide a forum for interdisciplinary discussions and networking with your peers.